A Prospective Study and Single-Center Experience: Effectivity of Fusion Prostate Biopsy in Biopsy-Naïve Patients
| Autor: | Gökhan Sönmez, Türev Demirtaş, Şevket Tolga Tombul, Ahmet Gur, Abdullah Demirtaş, Abdullah Golbasi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Prostate biopsy medicine.diagnostic_test genetic structures business.industry Urology General Engineering Magnetic resonance imaging Single Center medicine.disease prostate cancer combined biopsy Lesion Prostate cancer medicine.anatomical_structure Prostate Biopsy medicine targeted biopsy magnetic resonance imaging medicine.symptom Prospective cohort study business clinically significant cancer |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| Popis: | Objective Fusion prostate biopsy (FPB) has become a popular technique in biopsy-naive patients, though not accepted as a standard approach (yet). In this study, we aimed to present the clinical outcomes of biopsy-naive patients who underwent FPB. Material and methods The study included 400 biopsy-naive patients aged 45-75 years who had a prostate-specific antigen (PSA) level of 2-10 ng/ml and were detected with a Prostate Imaging-Reporting and Data System (PIRADS) ≥3 lesion on multiparametric prostate magnetic resonance imaging (mpMRI)-guided FPB. A combined biopsy (CB) was performed in each patient, in which 2-4 cores were obtained for suspicious lesions by targeted biopsy (TB) and then 12-core standard prostate biopsy (SPB) was conducted in the same session. Cancer detection rates, clinically significant prostate cancer (csPCa) detection rates, histological upgrading rates, and false negative rates were determined. Results The 400 patients had a mean age of 62.01±7.00 years and a mean PSA value of 6.84±1.87 ng/ml. Overall PCa detection rate was 50% (200/400). The csPCa detection rates for TB, SPB, and CB were 25.0%, 31.8%, and 44.0%, respectively (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|